BioNTech SE (BNTX)

86.17 -0.23 (-0.27%) At close: 04:00PM EDT

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6,133

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board	1.23M	N/A	1965
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board	809.76k	N/A	1967
Mr. Jens H. Holstein	CFO & Member of Management Board	1.42M	N/A	1963
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board	832.17k	N/A	1973
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board	1.02M	N/A	1979
Mr. Sean Marett	Chief Business Officer, Chief Commercial Officer & Member of Management Board	803.36k	N/A	1965
Dr. James Timothy Patrick Ryan Ph.D.	Chief Legal Officer & Member of the Management Board	601.72k	N/A	1975
Mr. Zach Taylor	Senior Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Dr. Katalin Kariko Ph.D.	Senior VP & External Consultant for RNA Protein Replacement Therapies	N/A	N/A	N/A
Dr. Oliver Henning Ph.D.	Senior Vice President of Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Corporate governance

BioNTech SE’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.